Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment

BACKGROUND: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. OBJECTIVE AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönfelder, Kristina, Schuh, Helene, Pfister, Frederick, Krämer, Julia, Eisenberger, Ute, Skuljec, Jelena, Hackert, Jana, Ruck, Tobias, Pfeuffer, Steffen, Fleischer, Michael, Gäckler, Anja, Hagenacker, Tim, Kribben, Andreas, Meuth, Sven G, Kleinschnitz, Christoph, Pul, Refik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521349/
https://www.ncbi.nlm.nih.gov/pubmed/34165361
http://dx.doi.org/10.1177/13524585211022719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521349/
https://www.ncbi.nlm.nih.gov/pubmed/34165361
http://dx.doi.org/10.1177/13524585211022719

Ejemplares similares